Organigram’s Sanity Group Signs Swiss Distribution Deal

Sanity Group, the German medical cannabis company that Canadian producer Organigram (OGI ) acquired in April 2026, has signed a distribution agreement to move its avaay Medical products into Swiss pharmacies. The agreement runs through Bogen Pharma AG, the distribution arm of Swiss operator Astrasana Holding AG, and gives avaay Medical access to a network of more than 20 pharmacies across Switzerland.

Financial terms were not disclosed. As a piece of business, a single-market distribution arrangement is modest. Its significance is what it signals: Organigram, having bought Sanity outright, is beginning to push branded product through the European platform it acquired rather than simply owning it on paper.

A small market the industry watches closely

Switzerland is not a volume market. It serves roughly 6,000 medical cannabis patients, a fraction of neighboring Germany’s caseload. But it draws outsized industry attention because its rules are unusually permissive — since a 2022 change to Swiss narcotics law, doctors can prescribe cannabis-based medicines without special federal approval — and because the country runs several of Europe’s most closely studied adult-use pilot programs. Switzerland is not an EU member, and its market sits outside the bloc’s frameworks.

Those pilots are part of what makes the market interesting to operators. Data presented at the European Cannabis Insights Summit in Berlin in June 2026 showed that across Switzerland’s eight pilot programs, 66% of participants reported no longer buying cannabis through illegal channels — the kind of evidence the wider European industry cites as it argues for broader reform.

The agreement itself is, at bottom, a supply story. Germany’s demand surge after it loosened its own cannabis laws pulled flower toward the larger market and left smaller neighbors short. Astrasana’s managing director, Yves Antoniazzi, said in announcing the partnership that existing supply relationships had proven inadequate as Swiss demand accelerated through 2025, and that Bogen Pharma has posted monthly revenue growth of around 20% since the start of that year. Canadian producers have spent the past year pushing medical flower into European markets as domestic margins compress; routing avaay Medical into Switzerland is a version of that move, run through an acquired local brand.

Sanity already had a Swiss foothold. Its Grashaus Projects subsidiary operates two licensed cannabis stores in the canton of Basel-Landschaft as part of a scientific adult-use pilot that has enrolled 1,800 participants since 2023 — about 3% of the canton’s adults. Telemedicine drives growth there much as it does in Germany, where remote prescribing has become a live policy fight.

What the deal means for Organigram

The Swiss agreement is an early, concrete example of Organigram putting its new European platform to work. Canada’s largest cannabis producer by market share announced in February 2026 that it would buy the rest of Berlin-based Sanity it did not already own, in a transaction valuing the company at up to €250 million. Sanity’s appeal was growth: its net revenue climbed from €9 million in 2023 to €60 million in 2025.

That €250 million figure rewards a closer reading, because announced and executed numbers rarely line up. Organigram framed it as a ceiling — an upfront payment plus an earnout of up to €113.8 million tied to Sanity hitting revenue and profit targets in the 12 months after closing. When the deal closed in April 2026, the upfront payment actually made was €107.3 million in cash and stock — below the €113.4 million Organigram had pitched in February. The remainder is contingent on performance.

The acquisition was financed partly through a private placement with British American Tobacco, which holds stakes in both companies and took Organigram shares rather than cash for its Sanity interest, alongside a senior secured credit facility and the final draw from a strategic investment pool Organigram had built with BAT funding. Sanity’s founder and chief executive, Finn Age Hänsel, stayed on after the close.

For Organigram, the Swiss deal is a proof point for the case it made to investors: that owning a European platform — local brands, regulatory expertise, pharmacy relationships — captures more of the value chain than exporting bulk flower. It is the same logic drawing other North American operators deeper into Europe. Curaleaf recently bought out the remaining stake in its German subsidiary, Four 20 Pharma, a bet that the continent’s medical markets are worth building inside rather than selling into.

What to watch next

The Swiss agreement does not yet demonstrate scale. It is distributed into a 6,000-patient market, and its direct financial contribution will be small against Organigram’s targets for the German business. The figure that matters is whether Sanity clears the performance thresholds that release the earnout — and whether deals like this one, repeated across Sanity’s operations in Switzerland, the UK, Poland, and the Czech Republic, accumulate into the platform Organigram has now paid more than €100 million upfront to control. Other Canadian producers are working the same opening from the export side, chasing international medical certification to reach European patients without buying their way in.